A golden tube following bioresorbable scaffold implantation

Sandeep Basavarajaiah, Harkaran Kalkat, Richard Watkin

Heartlands Hospital, University of Birmingham, Birmingham, United Kingdom




FIGURE 1 Angiography and optical coherence tomography in a patient with the diseased left anterior descending artery after bioresorbable scaffold implantation: **A** – well-apposed scaffolds at 6 months; **B** – continued good outcomes and persisting scaffolds at 2 years; **C** – continued good outcomes and complete resorption of the scaffolds at 5 years

Correspondence to:
Sandeep Basavarajaiah, MD,
MRCP, FESC, Heartlands Hospital,
Bordesley Green,
Birmingham B9 5SS,
United Kingdom, phone:
+44 121 4247478, email:
sandeep270478@gmail.com
Received: March 9, 2020.
Revision accepted: May 31, 2020.
Published online: May 11, 2020.
Kardiol Pol. 2020; 78 (7-8): 782-783
doi:10.33963/KP.15355
Copyright by the Author(s), 2020

A 57-year-old man with crescendo angina presented with a long segment of the left anterior descending artery (LAD) affected by diffuse disease, which could not be surgically revascularized (Supplementary material, Figure S1). He was successfully treated with a hybrid strategy. Three overlapping vascular bioresorbable scaffolds (BRS) were implanted and, proximally, a drug eluting stent was placed to avoid loss of a large diagonal branch owing to the thickness of the scaffolds (Supplementary material, Figure S2). Angiography and optical coherence

tomography (OCT) at 6-month (FIGURE 1A; Supplementary material, Figure S3) and 2-year follow-up (FIGURE 1B; Supplementary material, Figures S4 and S5) demonstrated positive remodeling of the vessel and persisting scaffolds that were fully endothelialized. 1.2 The patient continued to be asymptomatic at 5 years, and the repeat angiogram with OCT demonstrated no restenosis. More importantly, there was complete resorption of the scaffolds, mimicking a golden tube on OCT (FIGURE 1C; Supplementary material, Figures S6, S7, and S8) The benefits of BRS are

best reaped in such long, diffuse lesions, especially in the LAD. With BRS, a full-metal jacket is avoided and, since the scaffolds are absorbed, it can potentially provide the future option of coronary artery bypass grafting. Our patient can potentially have a graft to his LAD in the future if he develops new disease that could not have been possible earlier owing to the diffuse nature of the disease. If BRS were to return for clinical use, it should be reserved for such long, diffuse LAD lesions to reap the full benefit from the resorbable technology. There are some studies in which nonuniform absorption of scaffolds have been reported,3 but this may be related to underlying tissue composition (fibrocalcific), which may hinder the resorption. In addition, it may also reflect how well the scaffolds were originally deployed (embedded versus just opposed to the vessel wall). Well-embedded scaffolds are probably well resorbed compared with the one just opposed.

SUPPLEMENTARY MATERIAL

Supplementary material is available at www.mp.pl/kardiologiapolska.

ARTICLE INFORMATION

CONFLICT OF INTEREST None declared.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0), allowing third parties to download articles and share them with others, provided the original work is properly cited, not changed in any way, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at kardiologiapolska@ptkardio.pl.

HOW TO CITE Basavarajaiah S, Kalkat H, Watkin R. A golden tube following bioresorbable scaffold implantation. Kardiol Pol. 2020; 78: 782-783. doi:10.33963/KP.15355

REFERENCES

- 1 Basavarajaiah S, Qadir M. Hybrid strategy for diffuse coronary lesion. JACC Cardiovasc Interv. 2015; 8: 1518-1521.
- 2 Basavarajaiah S, Naganuma T, Watkin R. Bioresorbable vascular scaffolds for a long diffuse coronary lesion: insights from optical coherence tomography at 25-month follow-up. Kardiol Pol. 2018; 76: 928.
- 3 Gasior P, Parma R, Roleder T, Wojakowski W. Different absorption time of two absorb BVS implanted in the same artery: insights into mechanisms of late scaffold failure. Kardiol Pol. 2018; 76: 1277.